Field Trip launches a telehealth version of its ketamine-assisted therapy, via a partnership with Nue Life Health.
Field Trip launches a telehealth version of its ketamine-assisted therapy, via a partnership with Nue Life Health.
Mindset Pharma announces initial planning of its Phase 1 clinical trials for its first family of novel molecules.
Optimi Health announces the completion of its previously announced lab expansion for its Princeton, British Columbia facility.
Mind Medicine Inc announces strong clinical results from its Phase 2 clinical trial using MM-120 for the treatment of Generalized Anxiety Disorder (GAD).
Enveric Bioscience announces it is spinning off its cannabinoid R&D pipeline into a stand-alone entity.
A plethora of drug R&D opportunities. A multitude of badly under-served healthcare treatment markets. A medical "miracle"; an investment pot of gold.
Compass Pathways reports its Q1 for 2022. Net loss of $21.2 million on increased R&D expenses. Cash position of $243.7 million.
Compass Pathways announces the first-ever study of psilocybin therapy on autistic adults, using COMP360.
Cybin announces more early success with with its Kernel Flow(R) technology to measure the neurological effects of ketamine therapy.
Red Light Holland submits a new patent application for its microdosing kits.
Psychedelics Have Proven Potential To Disrupt Entire Mental Healthcare Industry
Get Your Guide To “Ground Floor” Opportunity In Psychedelic Stocks Now